Progress towards a vaccine for nontypable Haemophilus influenzae.
Nontypable Haemophilus influenzae is a common cause of human disease and is associated with significant morbidity and considerable societal cost. At present, measures to prevent nontypable H. influenzae disease are limited to prophylactic antibiotics and, on occasion, exogenous antibody preparations. However, because these interventions are often inadequate, there is interest in developing an effective vaccine. Given the marked diversity among epidemiologically unrelated strains and the frequent strain specificity of the immune response to infection, efforts have focused on identifying bacterial antigens that are highly conserved and capable of stimulating protective antibody. With the recent identification of several such antigens, attention must now turn toward selecting the appropriate combination of these molecules and determining the optimal strategy for their presentation to the immune system. The ultimate goal is to induce broad-based and long-lasting protection.
St Geme
J W
JW
Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.
D018829:Adhesins, Bacterial / Q000276:immunology; D000942:Antigens, Bacterial / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D006192:Haemophilus Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000276:immunology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018579:Patient Selection; D018110:Receptors, Lipoprotein / Q000276:immunology
D018829:Adhesins, Bacterial; D000942:Antigens, Bacterial; D018073:Haemophilus Vaccines; D018110:Receptors, Lipoprotein